Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs

episode

Biotech 2050 Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-29-2026 7AM EDT 4 min · 29 Sep 2026 · NPR News Now

7AM ET 09/29/2026 Newscast 3 min · 29 Sep 2026 · Fox News Hourly Update

Most replayed moment: The hidden dangers of hearing loss | Prof. Marcelo Rivolta 8 min · 29 Sep 2026 · ZOE Science & Nutrition

Overmedicated To Death: Former FDA Officer on Presley Gerber & The Psychiatric Crisis in America w/ Dr. Mary Talley Bowden, Dr. Josef Witt-Doerring & Ronald Owens Jr. – Ask Dr. Drew – Ep 670 1h 19m · 29 Sep 2026 · Ask Dr. Drew

Federal boost for Navitas 6 min · 29 Sep 2026 · Wall Street Breakfast

SpaceX Starship Finally Reached Orbit & Why Dudes Are Becoming Cat Dads 29 min · 29 Sep 2026 · Morning Brew Daily

Report any issue

Source

Recorded30 Oct 2024

Publisherfeeds.soundcloud.com ↗

Handlerec:2866629

Show notes

Biotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, which targets Parkinson's disease by aiming for disease modification rather than symptom management. Gene also discusses the challenges of biotech leadership, running clinical trials, and navigating the financial landscape, highlighting the dynamic intersection of science, business, and innovation in neurodegenerative diseases.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in